Hancock Whitney Corp Ligand Pharmaceuticals Inc Transaction History
Hancock Whitney Corp
- $2.92 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding LGND
# of Institutions
246Shares Held
17.5MCall Options Held
61KPut Options Held
7.8K-
Black Rock Inc. New York, NY2.87MShares$295 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$198 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$104 Million0.05% of portfolio
-
Macquarie Group LTD Australia, C3967KShares$99.2 Million0.1% of portfolio
-
Dimensional Fund Advisors LP Austin, TX709KShares$72.7 Million0.02% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.73B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...